Inflammatory disease Archives

dupilumab inflammation regeneron sanofi 1

News and Trends 16 Oct 2017

Biotech Power-Couple Sees Positive Phase II Results For Inflammatory Disease Drug

Regeneron and Sanofi’s drug, dupilumab, has met primary and secondary endpoints for the treatment of eosinophilic esophagitis. The biotech-biopharma giants have announced that their candidate, Dupilumab, demonstrated good efficacy during a Phase II trial. The drug is designed for use against eosinophilic esophagitis, a nasty inflammatory disease of the esophagus that makes it difficult to swallow. […]

October 16, 2017 - 3 minutesmins - By Alex Dale

More News! 13 Oct 2017

German Biotech Gets €47M To Treat Painful Inflammatory Disease

InflaRx has raised $55M (€47M) in a Series D fundraising in order to get its lead anti-inflammatory drug, IFX-1, through late-stage development. A year after its €31M Series C, InflaRx is closing a Series D round. The company has raised a total of $55M (€47M) from a team of US investors co-led by Bain Capital Life Sciences, […]

October 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 2 Oct 2017

New Swedish Pharma Bids for Anti-Inflammatory Drugs Without Side Effects

Swedish Gesynta Pharma has signed an agreement with Orexo to acquire a drug candidate to treat inflammatory diseases with fewer side effects. Based in Uppsala, Orexo has built a solid pipeline since its foundation in 1995, including three products currently in the market. The company has now struck a deal for one of its early-stage programs, OX-MPI, focused on inflammation. BI1029539, the […]

October 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Morphosys Janssen Guselkumab approval psoriasis

News and Trends 18 Sep 2017

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […]

September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

samsung bioepis imraldi humira adalimumab biosimilar tnf a

News and Trends 28 Aug 2017

Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody

Samsung Bioepis has announced the European Commission approved Imraldi, a biosimilar of AbbVie’s Humira (adalimumab), which has topped revenue charts for years. Samsung Bioepis’ Imraldi has now marketing authorization in the EU as a biosimilar of Humira (adalimumab) for the treatment of over 10 inflammatory indications, including rheumatoid arthritis, psoriasis, Crohn’s disease and ulcerative colitis. This makes […]

August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Jul 2017

Dutch Biotech Reports Positive Phase II Data on Rare Inflammatory Disease

Pharming has published Phase II data in The Lancet supporting its lead candidate as a treatment for the rare genetic disease hereditary angioedema. Pharming, one of the top biotechs in Leiden, specializes in recombinant protein technology. Its lead compound, ruconest, is a recombinant human C1 inhibitor protein. The results of a 32-patient Phase II study published […]

July 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Jul 2017

Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links

Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the […]

July 20, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 20 Jul 2017

Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies

Ablynx and Sanofi have entered a research collaboration and exclusive licensing agreement for up to eight nanobody candidates for immune and inflammatory disease. Ablynx, based in Belgium, develops nanobodies, single-domain antibodies inspired on those of camels and llamas that have the advantage of being much smaller than standard antibodies. This technology has caught the attention of Sanofi, […]

July 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

inflammatory disease imperial college london macrophage

News and Trends 12 Jul 2017

British Researchers “Calm Down” Macrophages to treat Inflammation

Imperial College London and Ergon Pharmaceuticals have a new enzyme target to treat inflammatory disease by reducing the activity of macrophages. Researchers at Imperial College London have developed a method to reprogram macrophages and reduce their inflammatory activity. The approach, published in Nature Communications, proved to reduce by more than half inflammation in the joints […]

July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Ose Immunotherapeutics bpifrance milestone bowel disease

News and Trends 22 Jun 2017

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

OSE Immunotherapeutics has successfully completed the necessary milestones to bring a treatment for autoimmune disease to the clinic, triggering a milestone payment from its partner Bpifrance. OSE Immunotherapeutics, based in Nantes, France, has received €2.6M from the French public investment agency Bpifrance after completing another milestone in the development of a therapy for inflammatory bowel disease. […]

June 22, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 15 Jun 2017

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling drug. At the 2017 Annual European Congress of Rheumatology, currently being held in Madrid, Novartis has presented new data showing that Cosentyx (secukinumab) keeps improving symptoms of ankylosing spondylitis after three years of treatment and […]

June 15, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 24 May 2017

French Biotech Enters New Agreement to Advance its IBD Immunotherapy

OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist for the treatment of IBD. In the end of last year, French OSE Immunotherapeutics joined forces with Servier to develop and commercialize its interleukin-7 antagonist (Effi-7) in a deal that could earn the biotech up […]

May 24, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Inflammatory disease

Biotech Power-Couple Sees Positive Phase II Results For Inflammatory Disease Drug

German Biotech Gets €47M To Treat Painful Inflammatory Disease

New Swedish Pharma Bids for Anti-Inflammatory Drugs Without Side Effects

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody

Dutch Biotech Reports Positive Phase II Data on Rare Inflammatory Disease

Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links

Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies

British Researchers “Calm Down” Macrophages to treat Inflammation

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

French Biotech Enters New Agreement to Advance its IBD Immunotherapy

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!